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Aging is associated with an increased incidence of cardiovascular disease and
thrombosis. Platelets play a major role in maintaining hemostasis and in thrombus
formation, making them a key player in thrombotic disorders. Whereas it is well-known
that platelet aggregability is increased in vascular diseases, the contribution of
age-related changes in platelet biology to cardiovascular risk is not well-understood.
Several lines of evidence support that platelets from older subjects differ in their function
and structure, making platelets more prone to activation and less sensitive to inhibition.
These age-related changes could lead to platelet hyperactivity and to the development
of a prothrombotic state in advanced age. This review will focus on platelet biochemical
modifications during aging and on the mechanisms by which these alterations could lead
to thrombotic disease.
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INTRODUCTION
Aging is accompanied by many biological changes at molecular and cellular levels. Senescence, the
most striking cellular alteration in aging, is a hyporeplicative state implicated in age-related diseases
(1). Senescent cells adopt a specific secretion signature rich in pro-inflammatory cytokines called
the senescence-associated secretory phenotype (SASP) (1). It has been suggested that SASP induces
changes in the functions of neighboring cells (2, 3), and some authors hypothesize that it might
potentially contribute to increased susceptibility to thrombosis in elders (4).
Cardiovascular disease is the first cause of death worldwide and its incidence is strongly
correlated with age (5). In both normal and pathological aging, platelets show increased
aggregability (6–11) which is however more pronounced in a pathological state (12, 13). Several
lines of evidence suggest that platelet hyperactivity observed in advanced age could be responsible
for vascular and thrombotic disease development (14–17). However, molecular mechanisms of
platelet hyperactivity in aging are only partially understood. A deeper understanding of the
biological mechanisms underlying the relationship between age-related changes in platelet biology
and cardiovascular disease could help improve treatment and preventive strategies. This review
explores biochemical changes in platelets during aging.
AGE-ASSOCIATED DECREASE IN PLATELET COUNT
Platelet count is inversely associated with age. A large study based on the Third National
Health and Nutrition Examination Survey including 12,142 American subjects showed a
significant decrease of 10 × 103 platelets/µL in individuals in the 60–69 year age group
as compared with those between the ages of 20–59 years, and of 20 × 103 platelets/µL in
patients aged over 69 years of age, after adjusting for many covariates such as nutritional
deficiencies, medication, inflammatory conditions, autoimmune or viral illnesses and consumption
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of alcohol and tobacco (18). This suggests that the drop in platelet
count with age is part of the biological aging process per se and
not only due to environmental factors.
Another large study on 33,258 subjects in France examined
full blood count normal references values by age and sex. It
showed the same tendency of platelet count being lower in older
adults vs. their younger counterparts (19). Many studies showed
that older women presented with higher platelet counts thanmen
of the same age (18–20). A tendency of a lower platelet count in
elderly people compared with young subjects was observed in two
other small studies, but was not considered statistically significant
(21, 22). Despite evidence of an inverse correlation between aging
and platelet count, the cause of the decline in platelet count
and the physiological consequences of this phenomenon in older
subjects remain to be elucidated. Two hypotheses have been put
forward in an attempt to rationalize this observation: (i) older
individuals have a lower stem cell reserve compared to younger
subjects; and (ii) a reduced platelet count confers a biological
advantage, so the individual with this characteristic may have a
better chance to reach an older age (18).
Interestingly, platelet count has been associated withmortality
among elders (23–25). Van der Bom et al. reported that platelet
count below 100 or above 400 × 109 L−1 is associated with
increased non-cardiovascularmortality such as cancer in a cohort
of 5,766 American and African-American patients of 65 years
and older (23). Another group has come to a similar conclusion,
i.e., they found a U-shaped all-cause mortality curve associated
with platelet count in 131, 308 Chinese patients of the same age
(24). A third group confirmed the association across all ethnic
groups (25). However, they found that the association between
mortality and thrombocytosis or thrombocytopenia was stronger
among non-Hispanic Whites compared with African-Americans
or Hispanics, highlighting the effect of genetic background in
age-related changes in platelet count.
Despite the decrease in platelet count during aging, reference
ranges are rarely age-adjusted, leading to misdiagnosis of
thrombocytopenia in the elderly. A study showed that a reference
range adjusted for age and sex is more strongly predictive of
all-cause mortality than the unadjusted platelet count reference
range (26). This led the authors to propose that age-adjusted
reference ranges might be useful in clinical practice to better
identify thrombocytopenic patients with a truly increased risk of
mortality (26).
ENHANCED PLATELET ACTIVITY IN THE
ELDERLY
One of the most documented changes in platelet function
during aging is platelet hyperactivity. Bleeding time decreases
significantly in aging, denoting a faster clot formation and
indirectly an enhanced platelet activity in the elderly (27, 28).
Furthermore, platelets from older men and women have a greater
sensitivity to aggregation induced by classical agonists. Platelets
aggregation of older subjects occurs at a lower concentration
threshold of ADP (8–11, 22, 29), epinephrine (6, 7, 10, 11),
collagen (22) and arachidonic acid (10) than platelets from
younger subjects. Meade et al. reported an increase in platelet
aggregability of ∼8% per decade of age, calculated by the EC50
of ADP in a cohort of 958 participants of all ages (8). At all ages,
aggregability was found to be more pronounced in women than
inmen (8, 10). A recent study suggests that age-related changes in
platelet behavior on vonWillebrand factor are more pronounced
in women than in men (30), also supporting the concept that
the aging process could affect platelet function differently in
both sexes.
Furthermore, β-thromboglobulin and platelet factor 4 (PF4),
two proteins secreted from platelets α-granules, are both found
at a significantly higher level in plasma of older compared
with younger subjects (29, 31). This is consistent with the
hyperaggregability observed in elderly individuals since platelets
release their granule content during activation. Interestingly, PF4
has also been found to have a procoagulant effect (32), showing
that the age-related prothrombotic state is probably due to a
number of biological changes in the thrombotic pathway, not
only occurring in platelets themselves.
The mechanisms of this age-related platelet hyperactivity
remain unclear. Bastyr et al. have tested the hypothesis
that modifications in phosphoinositide turnover, an important
signaling mechanism of platelet activation, may be responsible
for platelet hyperactivity in aging (29). They have found that
platelet phosphoinositide turnover is enhanced in aging and
correlates positively with platelet aggregation and plasma β-
thromboglobulin levels.
It has also been suggested that there could be a functional
or expressional change in platelet α and β-adrenoreceptors (33),
however the reported literature is conflicting. These receptors,
respectively, enhanced or inhibited platelet aggregation induced
by epinephrine and noradrenaline by decreasing or increasing
platelet cAMP levels. Yokoyama et al. observed an increase in
α-adrenoreceptor binding capacity in platelets of elderly people
without change in binding affinity (7). However, two other groups
have observed the opposite, i.e., a decrease in α-adrenoreceptor
binding capacity (6, 34). Finally, another study suggested a
decrease of β-adrenoreceptor affinity but an unchanged binding
capacity in older subjects (35).
CHANGES IN THE PLATELET-SEROTONIN
SYSTEM IN ADVANCED AGE
Serotonin is a vasoactive molecule stored in platelet granules and
released in plasma during platelet activation. Serotonin is also
known to induce platelet shape change and boost epinephrine-
and ADP-induced aggregation (33, 36). According to Gleerup
et al., platelets from patients aged between 72 and 86 years old
have a higher sensitivity and an increased responsiveness to
serotonin than platelets from subjects 18 to 27 years of age (33).
They propose that it can be an important contributing factor of
increased platelet aggregability in the elderly.
On the other hand, it has been reported that platelet serotonin
content decreases with age (36, 37). Diminished serotonin
platelet content and an increased plasma serotonin level is also
observed in patients with type 1 or type 2 diabetes and in
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patients suffering from peripheral vascular diseases compared
with correspondingly aged healthy volunteers (36). This leads to
the suggestion that platelet hyperactivity can cause an increased
release of serotonin in plasma which then feeds back to platelet
hyperactivity and may thus play a role in the pathogenesis of
atherothrombotic diseases.
RELATIONSHIP BETWEEN OXIDATIVE
STRESS, AGING, AND PLATELET
HYPERREACTIVITY
The human and animal aging process is accompanied by an
increase in oxidative stress (38–40). Among biological systems
modified by oxidative stress, the cardiovascular system is
particularly sensitive to a misbalance in reactive oxygen species
(ROS), which has been associated with an increased risk of
cardiovascular events (38, 40). ROS also play a role in platelet
activation by acting as a second messenger or by producing
oxidized proteins important in platelet aggregation (38, 41),
which could explain the greater propensity toward thrombosis in
older individuals. Free radicals induce modifications of protein
structures notably by carbonylation or cross-linking in many
cell types. Those impaired proteins are therefore targeted by
proteolytic enzyme as a mechanism of defense against oxidative
damage. In aging, it is suggested that there is an accumulation
of carbonylated proteins which could lead to the development
of diseases such as diabetes, atherothrombosis and cancer. It
has been observed that aging increases the rate of carbonylated
proteins in platelets of rats (42), hamsters (42) and humans
(42, 43), providing a biologically-plausible mechanism of platelet
dysfunction. Platelet carbonyl content is even more sharply
increased in type 2 diabetes when compared with healthy controls
of the same age (42), further supporting the notion of ROS-
induced platelet hyperactivity. Oxidative stress can also modify
reactions involving disulfide bond formation, which can lead to
activation or inactivation of a number of proteins implicated
in different cellular pathways. For example, oxidative stress
increases the activity of platelet membrane protein disulfide
isomerase which activates several integrins by disulfide bond
isomerization (44). Themost important among these is the αIIbβ3
integrin, which undergoes partial reduction of disulfide bonds
during activation (44–47). Disruption of this finely-tuned balance
in αIIbβ3 integrin activation can thus lead to altered thrombotic
susceptibility (47). This is another of many mechanisms by
which oxidative stress could contribute to thrombus formation,
reviewed by several authors (39, 40, 45, 48).
Nitric oxide (NO) exerts its antithrombotic effect by inducing
vasodilation and by inhibiting platelet aggregation via the
activation of platelet guanylate cyclase (GC) generating cGMP,
which finally reduces intracellular free calcium levels (40, 49).
However, NO can also contribute to oxidative stress through
generation of oxidative species such as ONOO−, which can
evolve into free radicals and cause cellular damage leading to
several pathological mechanisms (50, 51). In order to investigate
if age influences the platelet NO signaling system, Michimata
et al. have measured GC activity in response to an exogenous NO
donor in platelets of individuals of different ages (52). They found
a decrease of the enzyme activity in older men (mean age 51.5
years) compared with younger men (mean age 29.5 years). Thus,
the efficiency of the NO/GC/cGMP platelet pathway regulating
aggregation may be modified in aging. Similarly, two other
groups have examined the variation of cGMP levels in platelets
with age (50, 53). Both groups showed a significant inverse
correlation between cGMP platelet levels and age, suggesting a
decrease in the inhibitory signaling pathway, which is consistent
withMichimata’s et al. results. Surprisingly, an increase in platelet
nitric oxide synthase (NOS) activity in aging has been described
(50), which seems contradictory with the cGMP decrease. A
similar increase in platelet NOS activity and decrease in cGMP
level have also been observed in 24-month-old rats, showing that
this phenomenon is consistent in different species (54). Many
hypotheses have been postulated to explain this contradiction,
notably the possibility that the excess of NO produces higher
amounts of oxidative reactive species such as ONOO− which
could potentially inhibit GC by targeting its iron/sulfur
cluster (50).
A recent study suggests that hydrogen peroxide, an oxidative
molecule, plays a key role in the platelet hyperactivity observed in
aged mice (55). They found that platelets from old mice produce
higher levels of H2O2 when stimulated with thrombin in vitro
than platelets from younger mice. Furthermore, when they used
PEG-catalase to selectively degrade intraplatelet H2O2 in 4- and
18-month-old mice, the authors observed the complete reversal
of the age-dependent platelet hyperactivation; i.e., platelet activity
of young and old mice were reduced to the same level (marked
by a similar percentage of fibrinogen binding and integrin αIIbβ3
activation). These findings are consistent with previous work
showing that treatment with catalase inhibits platelet activation
by collagen (56). The authors proposed that the increased platelet
production of peroxide observed in aged mice results from
enhanced NADPH oxidase/superoxide dismutase pathway. This
was further supported by qPCR data showing increased NADPH
oxidase regulatory subunit and superoxide dismutase-1mRNA in
platelets of 18-month-old mice. Together, these findings suggests
a critical role of this oxidant molecule in platelet hyperactivity
during aging.
Surprisingly, recent human andmice data suggest that beyond
a certain age (∼80 years for human, ∼14 months for mice),
intraplatelet antioxidant reserves are increased, and consequently
lead to decreased reactive oxygen species platelet content and
a reduction in platelet activity and apoptosis (57). The causes
of this observation are still unknown, but it could be the
consequences of a biological mechanism to counteract the
increase of oxidative stress burden in aging.
AGE-RELATED ALTERATIONS IN
VASCULAR PROSTAGLANDINS
Vascular homeostasis relies on a balance between prostacyclin,
which induces vasodilation and inhibits platelet activation,
and thromboxane A2, which does the opposite (58).
While thromboxane A2 is principally synthetized and
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released by platelets, prostacyclin is essentially produced by
vascular endothelium.
Giani et al. have examined the sensitivity of platelets of
young and old rats to exogenous prostacyclin in vivo (59).
They found that platelets from 11-month aged rats were more
sensitive to the inhibitory effect on aggregation of prostacyclin
compared with 1-month old animals. They propose that this
could be a natural mechanism to counteract the enhanced
aggregability observed in older rats. On the other hand, Modesti
et al. studied the prostacyclin receptor by performing binding
assays. They found a significant decrease of expression of the
prostacyclin receptor in platelets of healthy humans with age
but no changes in binding affinity (60). Interestingly, a similar
decrease in the number of platelet prostacyclin receptors has been
observed in patients with spontaneous angina (61), suggesting
that this age-related downregulation could be the beginning of
an imbalance in vascular homeostasis leading eventually to a
pathological phenotype.
In order to explore the effect of increasing age on
thromboxane A2 and prostacyclin production, Reilly et al. have
studied the urinary excretion of 2,3-dinor-thromboxane B2 and
2,3-dinor-6-keto-PGF1α, metabolites of thromboxane A2 and
prostacyclin, respectively (27). They found that both metabolites
were significantly higher in individuals aged over 50 years
old than in younger individuals, suggesting that prostacyclin
and thromboxane A2 biosynthesis is increased with age. This
observation has been confirmed later by a second group who
found a positive correlation between the urinary excretion
of 11-dehydro-thromboxane B2, another stable metabolite of
thromboxane A2, and age in 833 patients with atrial fibrillation
(62). Furthermore, in this study, patients with elevated 11-
dehydro-thromboxane B2 excretion experienced significantly
more cardiovascular events during the 40 month follow-up.
CONTRIBUTION OF AGE-RELATED
PLASMA MEMBRANE MODIFICATIONS TO
PLATELET HYPERACTIVITY
The cell membrane composition is modified in the aging
process, notably with a higher total amount of cholesterol, and
those changes can affect diverse biochemical functions of the
cell such as transcellular signalization or cell membrane ion
transport (63–65). An increase in the lipid structural order,
and consequently a decrease in membrane fluidity, has been
shown in human lymphocyte membranes and in brain cells of
mice and rats (63, 66). Cohen et al. were the first to observe
similar membrane structural changes in human platelets during
aging (67). Others have also seen a positive correlation between
membrane structural order in human platelets, increasing age
and serum cholesterol levels (67–69). An increase in lipid
peroxide membrane composition, which promotes crosslink
lipid-protein interactions in the membrane, has also been
reported in platelets of aged rats and appears to contribute to
decreased membrane fluidity (70). Interestingly, an increase in
platelet membrane structural order in vitro is linked with a higher
sensitivity to aggregation induced by ADP and epinephrine (71,
72) and a higher production of thromboxane A2 (73, 74). This




The platelet transcriptome, which includes thousands of mRNAs,
miRNAs, long non-coding RNAs and other types of transcripts,
has long been considered static (75). However, recent advances
have rather shown that the platelet transcriptome changes
dynamically in response to inflammation, cancer and other
pathological states (76). Age-related modifications in the platelet
transcriptome have been suggested to govern platelet function
changes in aging (77, 78). RNA-sequencing of platelets from
young (aged < 45 years) and older individuals (aged > 64 years)
revealed a total of 514 transcripts that are expressed differently in
both groups (78). It is also suggested that the platelet proteome
of children, adults and elders differs, but little is known about
age-related changes in the expression of those proteins and
their biological consequences (78, 79). Interestingly, it has been
shown that the transcriptome of mouse cardiac cells varies in
the presence of hypertension and in function of age, leading to
variation in regulation of platelet signaling and proinflammatory
mechanisms (80). This suggests that age-related changes in
the transcriptome of other cell types can also modify platelet
function indirectly, highlighting the complexity of transcriptome
regulation in aging.
Campbell et al. have examined the changes in the platelet-
monocyte relationship with increasing age (78). They observed
that monocytes produce increased levels of interleukin-8 (IL-
8) and monocyte chemotactic protein 1 (MCP-1) when co-
incubated with platelets from older patients compared with
platelets from younger patients. They suggest that granzyme A,
a serine protease with increased intraplatelet expression in older
patients, is responsible for excessive production of these two pro-
inflammatory cytokines in monocytes. This highlights the cross-
talk between platelets and immune cells as a possible mechanism
by which alterations in the platelet transcriptome and proteome
could contribute to inflammatory diseases in aging.
AGE-RELATED HORMONAL CHANGES ON
PLATELET FUNCTION IN WOMEN
Although men are more susceptible to suffer from cardiovascular
disease than women (81), this difference of morbidity between
the sexes is reduced after the age of menopause. Despite
this, hormone replacement therapy (as well as hormonal
contraception) does not mitigate the increased cardiovascular
risk in women and may even worsen it (82–84). A number of
investigators have studied the role of estrogen level changes in
blood on platelet function and the link with the normal aging
process in women.
Platelets and megakaryocytes express both estrogen receptors
ERα and ERβ (ERβ being predominant), on which estrogen
can bind and modulate gene transcription of some proteins
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and enzymes required in platelet function such as integrin β3,
CD34, platelet-derived growth factor, and NOS (85). Estrogen
is also known to inhibit platelet aggregation in vitro via the
NO/GC/cGMP pathway (86, 87).
Animal studies have shown that decreased estrogen levels per
se directly affect platelet function. According to Jayachadran et al.
a surgically-inducedmenopause in pigs increases significantly the
expression of estrogen receptors on platelets (88). In this model,
they also observed an increased expression of heat shock proteins
70 and 90 in platelets, which act as ER chaperones to maintain
their conformation until they bind to their ligand. An increase
in NOS activity, eNOS expression and cGMP concentration have
also been observed in ovariectomized pigs (88).
It has been suggested that the hormonal cycle in women
of procreating age may influence platelet activity. Some
authors have observed an increased platelet function during
the luteal phase compared with the follicular phase and
have found a negative correlation between progesterone
levels and platelet reactivity (89–91), while others observed
no significant differences in platelet aggregation responses
during the menstrual cycle (92). Moreover, women taking
oral contraception (which contains estrogen and progestogen)
have greater platelet count and less spontaneous platelet
aggregation than those not taking an anovulant (92).
Thus, the effect of hormones on platelet reactivity is
not clear.
Few well-controlled aging studies have considered the
hormonal status of women as a covariate of platelet function,
and therefore it is difficult to ascertain the contribution of
hormonal changes on the increased thrombotic risk observed
with aging (85). Indeed, when looking at platelet function in peri-
menopausal women, it may be difficult to dissociate hormonal
factors that vary with age from the aging process in platelets
themselves. To examine the effect of menopause on platelet
function with minimal impact of age, Lundberg Slingsby et al.
designed a study in which they formed two groups of women:
late premenopausal women and recent postmenopausal women
with a mean difference age between groups of only 4 years (93).
They found that platelets from postmenopausal women have
a greater propensity to aggregation by classical agonists (ADP,
TRAP, collagen, epinephrine) than premenopausal women.
Thus, the menopause-induced drop in estrogen levels may
contribute to platelet hyperactivity in women undergoing the
natural aging process. Further investigations are required to fully
understand the influence of estrogen and the consequences of
menopause on platelet function of women, and their interaction
with aging.
AGING, PLATELET HYPERACTIVITY AND
COEXISTING DISEASES
Most studies have reported direct associations between
biochemical age-related changes in platelets and their
hyperaggregability. However, causality is difficult to establish
in observational studies, and inverse causality has also
been suggested. Kurabayashi et al. have suggested that
the enhanced platelet activity observed in the elderly is
caused by underlying atherosclerosis rather than by the
aging process (94). They have examined shape change and
peroxidase content of platelets from a small group of young
and old subjects with or without atherosclerosis. They have
observed no significant differences in these parameters between
young and old healthy individuals. In elderly subjects with
atherosclerosis on the other hand, platelets presented more
frequently in an activated state (formation of pseudopods)
and their peroxidase content was decreased. Although the
small sample size and absence of longitudinal follow-up
somewhat mitigates their conclusion, Kurabayashi et al.
raise an important question by asking whether platelet
hyperactivity in the elderly is caused by aging or by a
coexisting onset of an atherosclerotic state. Adequately
controlled longitudinal studies are thus required to answer
this important question.




Platelet count ↓ (18–20)
PLATELET ACTIVITY
Bleeding time ↓ (27, 28)
Platelet sensitivity to agonists ↑ (6–11, 22, 29)
β-thromboglobulin plasma level ↑ (29, 31)






Controversial (7) (↑), (6, 34)
(↓)
Platelet β-adrenoreceptor affinity ↓ (35)
PLATELET SEROTONIN SYSTEM
Platelet sensitivity to serotonin ↑ (33)
Platelet serotonin content ↓ (36, 37)
PLATELETS AND OXIDATIVE STRESS
Rate of intraplatelet carbonylated
proteins
↑ (42, 43)
Intraplatelet GC activity ↓ (52)
Intraplatelet cGMP levels ↓ (50, 53, 54)
Intraplatelet NOS activity ↑ (50, 54)
Intraplatelet production of H2O2 ↑ (55)
PLATELETS AND PROSTAGLANDIN PATHWAYS




Thromboxane A2 production ↑ (27, 62)





Platelet lipid peroxide membrane
composition
↑ (70)
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CONCLUSION
In conclusion, aging is associated with an increase in platelet
activity and a higher rate of vascular and thrombotic disease.
Platelets of elderly and young humans significantly differ in
terms of number, activity and structure (see Table 1). These
age-related differences are closely linked to the prothrombotic
state observed in the elderly population; however, the nature
of this link remains only partially defined. Indeed, it is still
not clear whether platelet hyperactivity and vascular disease
develop concomitantly or if one is the consequence of the other.
Moreover, in addition to age, many other environmental and
genetic factors can influence platelet function such as elevated
plasma cholesterol, tobacco and alcohol consumption, diabetes,
hypertension and sexual hormones (11). Although some studies
have taken into account these covariates in their analyses, it is
impossible to rule out the presence of a confounding variable in
such complex traits. Therefore, additional studies are required
to fully elucidate the connection between molecular changes
in platelets and pathophysiological changes in the vascular
system during aging. A better understanding of the mechanisms
underlying modifications of platelet function in aging could
lead to the development of better-tailored treatments to curb
thrombosis in this at-risk population.
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